Titre : Vibrio cholerae

Vibrio cholerae : Questions médicales fréquentes

Termes MeSH sélectionnés :

Double-Blind Method
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vibrio cholerae : Questions médicales les plus fréquentes", "headline": "Vibrio cholerae : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vibrio cholerae : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-28", "dateModified": "2025-04-22", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vibrio cholerae" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Vibrio", "url": "https://questionsmedicales.fr/mesh/D014733", "about": { "@type": "MedicalCondition", "name": "Vibrio", "code": { "@type": "MedicalCode", "code": "D014733", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vibrio cholerae non-O1", "alternateName": "Vibrio cholerae non-O1", "url": "https://questionsmedicales.fr/mesh/D044163", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae non-O1", "code": { "@type": "MedicalCode", "code": "D044163", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.075" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae O1", "alternateName": "Vibrio cholerae O1", "url": "https://questionsmedicales.fr/mesh/D041241", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae O1", "code": { "@type": "MedicalCode", "code": "D041241", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.151" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae O139", "alternateName": "Vibrio cholerae O139", "url": "https://questionsmedicales.fr/mesh/D041242", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae O139", "code": { "@type": "MedicalCode", "code": "D041242", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.200" } } } ], "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae", "alternateName": "Vibrio cholerae", "code": { "@type": "MedicalCode", "code": "D014734", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Firdausi Qadri", "url": "https://questionsmedicales.fr/author/Firdausi%20Qadri", "affiliation": { "@type": "Organization", "name": "Infectious Diseases Division, icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh." } }, { "@type": "Person", "name": "Munirul Alam", "url": "https://questionsmedicales.fr/author/Munirul%20Alam", "affiliation": { "@type": "Organization", "name": "International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh." } }, { "@type": "Person", "name": "Shanta Dutta", "url": "https://questionsmedicales.fr/author/Shanta%20Dutta", "affiliation": { "@type": "Organization", "name": "National Institute of Cholera and Enteric Diseases, NICED-JICA Building, 57 Dr. S.C. Banerjee Road, Beliaghata, Kolkata, 700 010, India." } }, { "@type": "Person", "name": "Shelley M Payne", "url": "https://questionsmedicales.fr/author/Shelley%20M%20Payne", "affiliation": { "@type": "Organization", "name": "Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA payne@utexas.edu." } }, { "@type": "Person", "name": "Bibhuti Bhusan Pal", "url": "https://questionsmedicales.fr/author/Bibhuti%20Bhusan%20Pal", "affiliation": { "@type": "Organization", "name": "Microbiology Division, ICMR-Regional Medical Research Centre, Chandrasekharpur, Bhubaneswar, 751023, Orissa, India. Electronic address: bbpal_rmrc@yahoo.co.in." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial.", "datePublished": "2022-09-22", "url": "https://questionsmedicales.fr/article/36136861", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MPG.0000000000003622" } }, { "@type": "ScholarlyArticle", "name": "Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.", "datePublished": "2022-07-28", "url": "https://questionsmedicales.fr/article/35896988", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s10194-022-01458-0" } }, { "@type": "ScholarlyArticle", "name": "The minimal important difference in obsessive-compulsive disorder: An analysis of double-blind SSRI trials in adults.", "datePublished": "2024-09-20", "url": "https://questionsmedicales.fr/article/39301594", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1192/j.eurpsy.2024.1768" } }, { "@type": "ScholarlyArticle", "name": "A Dietary Supplement in the Management of Patients with Lumbar Osteochondrosis: A Randomized, Double-Blinded, Placebo-Controlled Study.", "datePublished": "2024-08-14", "url": "https://questionsmedicales.fr/article/39203831", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/nu16162695" } }, { "@type": "ScholarlyArticle", "name": "The clinical effect of benesco™ on reflux symptoms: A double-blind randomized placebo-controlled trial.", "datePublished": "2023-07-10", "url": "https://questionsmedicales.fr/article/37427678", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/nmo.14648" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Bactéries", "item": "https://questionsmedicales.fr/mesh/D001419" }, { "@type": "ListItem", "position": 3, "name": "Proteobacteria", "item": "https://questionsmedicales.fr/mesh/D020560" }, { "@type": "ListItem", "position": 4, "name": "Gammaproteobacteria", "item": "https://questionsmedicales.fr/mesh/D020563" }, { "@type": "ListItem", "position": 5, "name": "Vibrionaceae", "item": "https://questionsmedicales.fr/mesh/D014737" }, { "@type": "ListItem", "position": 6, "name": "Vibrio", "item": "https://questionsmedicales.fr/mesh/D014733" }, { "@type": "ListItem", "position": 7, "name": "Vibrio cholerae", "item": "https://questionsmedicales.fr/mesh/D014734" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vibrio cholerae - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vibrio cholerae", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vibrio cholerae", "description": "Comment diagnostiquer une infection par Vibrio cholerae ?\nQuels tests sont utilisés pour confirmer le choléra ?\nQuels symptômes indiquent une infection par Vibrio cholerae ?\nQuelle est la période d'incubation du choléra ?\nComment différencier le choléra d'autres diarrhées ?", "url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vibrio cholerae", "description": "Quels sont les principaux symptômes du choléra ?\nComment se manifeste la déshydratation dans le choléra ?\nLe choléra peut-il être asymptomatique ?\nQuels signes indiquent une déshydratation sévère ?\nLes symptômes du choléra apparaissent-ils rapidement ?", "url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vibrio cholerae", "description": "Comment prévenir l'infection par Vibrio cholerae ?\nLa vaccination contre le choléra est-elle efficace ?\nQuelles mesures d'hygiène sont recommandées ?\nComment l'eau potable peut-elle prévenir le choléra ?\nLes voyages dans des zones à risque nécessitent-ils des précautions ?", "url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vibrio cholerae", "description": "Quel est le traitement principal du choléra ?\nLes antibiotiques sont-ils nécessaires pour le choléra ?\nComment prévenir la déshydratation dans le choléra ?\nQuels médicaments sont utilisés pour traiter le choléra ?\nLe traitement du choléra est-il efficace ?", "url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vibrio cholerae", "description": "Quelles sont les complications possibles du choléra ?\nLe choléra peut-il entraîner la mort ?\nComment la déshydratation affecte-t-elle le corps ?\nQuelles sont les conséquences à long terme du choléra ?\nLe choléra peut-il causer des épidémies ?", "url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vibrio cholerae", "description": "Quels sont les facteurs de risque du choléra ?\nLes enfants sont-ils plus à risque de choléra ?\nComment la malnutrition influence-t-elle le choléra ?\nLes personnes vivant dans des zones urbaines sont-elles à risque ?\nLes voyageurs peuvent-ils être exposés au choléra ?", "url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par Vibrio cholerae ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par culture de selles ou tests PCR pour détecter la bactérie." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer le choléra ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de culture des selles et les tests rapides de détection d'antigènes sont utilisés." } }, { "@type": "Question", "name": "Quels symptômes indiquent une infection par Vibrio cholerae ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent diarrhée aqueuse, vomissements et déshydratation rapide." } }, { "@type": "Question", "name": "Quelle est la période d'incubation du choléra ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "La période d'incubation est généralement de 1 à 5 jours après l'exposition." } }, { "@type": "Question", "name": "Comment différencier le choléra d'autres diarrhées ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le choléra se caractérise par une diarrhée aqueuse profuse et une déshydratation rapide." } }, { "@type": "Question", "name": "Quels sont les principaux symptômes du choléra ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux symptômes sont diarrhée aqueuse, vomissements, crampes abdominales." } }, { "@type": "Question", "name": "Comment se manifeste la déshydratation dans le choléra ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "La déshydratation se manifeste par soif intense, sécheresse de la peau et fatigue." } }, { "@type": "Question", "name": "Le choléra peut-il être asymptomatique ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines personnes peuvent être porteuses sans présenter de symptômes." } }, { "@type": "Question", "name": "Quels signes indiquent une déshydratation sévère ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent confusion, tachycardie, hypotension et urines très rares." } }, { "@type": "Question", "name": "Les symptômes du choléra apparaissent-ils rapidement ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent apparaître rapidement, souvent dans les 24 heures." } }, { "@type": "Question", "name": "Comment prévenir l'infection par Vibrio cholerae ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par l'accès à l'eau potable, l'hygiène et la vaccination." } }, { "@type": "Question", "name": "La vaccination contre le choléra est-elle efficace ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccins peuvent réduire le risque d'infection, surtout en zones à risque." } }, { "@type": "Question", "name": "Quelles mesures d'hygiène sont recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Se laver les mains fréquemment et consommer des aliments bien cuits sont essentiels." } }, { "@type": "Question", "name": "Comment l'eau potable peut-elle prévenir le choléra ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'eau potable et propre empêche l'ingestion de Vibrio cholerae, réduisant le risque." } }, { "@type": "Question", "name": "Les voyages dans des zones à risque nécessitent-ils des précautions ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est conseillé de se faire vacciner et de suivre des mesures d'hygiène strictes." } }, { "@type": "Question", "name": "Quel est le traitement principal du choléra ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal est la réhydratation orale ou intraveineuse selon la gravité." } }, { "@type": "Question", "name": "Les antibiotiques sont-ils nécessaires pour le choléra ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les antibiotiques peuvent être utilisés pour réduire la durée de la diarrhée et la gravité." } }, { "@type": "Question", "name": "Comment prévenir la déshydratation dans le choléra ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La réhydratation rapide avec des solutions de réhydratation orale est essentielle." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour traiter le choléra ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les antibiotiques comme la doxycycline ou l'azithromycine sont souvent prescrits." } }, { "@type": "Question", "name": "Le traitement du choléra est-il efficace ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un traitement rapide et approprié est très efficace pour réduire la mortalité." } }, { "@type": "Question", "name": "Quelles sont les complications possibles du choléra ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent déshydratation sévère, choc hypovolémique et insuffisance rénale." } }, { "@type": "Question", "name": "Le choléra peut-il entraîner la mort ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement rapide, le choléra peut être mortel en raison de la déshydratation." } }, { "@type": "Question", "name": "Comment la déshydratation affecte-t-elle le corps ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La déshydratation peut entraîner des déséquilibres électrolytiques et des défaillances organiques." } }, { "@type": "Question", "name": "Quelles sont les conséquences à long terme du choléra ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les conséquences peuvent inclure des problèmes de santé persistants, comme des troubles digestifs." } }, { "@type": "Question", "name": "Le choléra peut-il causer des épidémies ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le choléra peut provoquer des épidémies, surtout dans des conditions d'hygiène précaires." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque du choléra ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'accès limité à l'eau potable, la malnutrition et l'absence d'hygiène." } }, { "@type": "Question", "name": "Les enfants sont-ils plus à risque de choléra ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les enfants et les personnes âgées sont plus vulnérables aux complications du choléra." } }, { "@type": "Question", "name": "Comment la malnutrition influence-t-elle le choléra ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "La malnutrition affaiblit le système immunitaire, augmentant le risque d'infection par choléra." } }, { "@type": "Question", "name": "Les personnes vivant dans des zones urbaines sont-elles à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les zones urbaines surpeuplées avec un accès limité à l'eau potable sont à risque." } }, { "@type": "Question", "name": "Les voyageurs peuvent-ils être exposés au choléra ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyageurs dans des régions endommagées par le choléra doivent prendre des précautions." } } ] } ] }

Sources (10000 au total)

Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial.

Pediatric irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with variable response to various therapeutic agents. Psyllium has been proven to be effective in adults; howe... In this double-blind randomized controlled trial, 43 children were assigned to psyllium arm (Group A) and 38 into placebo arm (Group B). Severity is assessed at baseline and after 4 weeks of treatment... Mean ages (±SD; in years) of Groups A and B were 9.87 (2.7) and 9.82 (3.17), respectively, with median duration of illness of 12 months. At baseline, type, severity, and parameters (IBS-SSS) of IBS we... Psyllium husk is effective for the therapy of pediatric IBS when compared with placebo in short term....

Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.

Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated efficacy and good tolerability in patients with episodic migraine in previous phase 3 trials.... This phase 3 study was conducted at 40 centers in China (n = 26), India (n = 10), and Russia (n = 4). Eligible adult patients with episodic migraine were randomized in a 1:1 ratio to receive monthly g... In total, 520 patients were randomized and received at least one dose of galcanezumab (N = 261) or placebo (N = 259). The least squares (LS) mean reduction from baseline in monthly MHDs over 3 months ... Galcanezumab 120 mg once monthly was effective and well tolerated in patients with episodic migraine from China, India, and Russia.... ClinicalTrials.gov Identifier NCT03963232 (PERSIST), registered May 24, 2019....

The minimal important difference in obsessive-compulsive disorder: An analysis of double-blind SSRI trials in adults.

The change in symptoms necessary to be clinically relevant in obsessive-compulsive disorder (OCD) is currently unknown. In this study, we aimed to create an empirically validated threshold for clinica... We analyzed individual participant data from short-term, double-blind, placebo-controlled registration trials of selective serotonin reuptake inhibitors in adult OCD patients. Data were collected from... We included 7 trials with a total of 1216 patients. The CGI-scores and YBOCS were moderately to highly correlated. The MID corresponded to 4.9 YBOCS points (95% CI 4.4-5.4) for the full sample, or a 2... By linking the YBOCS to the CGI-I, this is the first study to propose an MID in OCD trials. Having a clearly defined MID can guide future clinical research and help interpretation of efficacy of exist...

The clinical effect of benesco™ on reflux symptoms: A double-blind randomized placebo-controlled trial.

Gastroesophageal reflux disease (GERD) is one of the most prevalent gastrointestinal diseases in the western world. Lifestyle modifications and proton pump inhibitors (PPIs) form the basis of the mana... We performed a double-blind randomized placebo-controlled trial in participants with reflux symptoms. Participants were assigned randomly (1:1) to receive 6 weeks of benesco™ (three times daily one lo... One hundred participants were randomized. Treatment success was seen in 18 (39%) of 46 participants in the intervention group versus 21 (47%) of 45 in the placebo group (p = 0.468). In the interventio... In our trial benesco™ showed no significant benefit over placebo at group level....

Turpentine Ointment in Bacterial Skin Infections: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial.

Turpentine-containing substances are considered effective in treating cutaneous bacterial infections, but reliable clinical data are scant.... We investigated the efficacy and safety of an ointment containing larch turpentine (from Larix decidua), eucalyptus oil (from Eucalyptus globulus), and turpentine oil (from Pinus pinaster) in outpatie... 116 outpatients with skin abscesses used verum or placebo for 10 days. Sum score of the patient's discomforts, changes in abscess size, rate of therapeutic success, and complete healing served as outc... Fifty-four patients were treated with verum and 56 with placebo. According to the patient's discomfort sum score, patients in the verum group showed a better improvement compared to the placebo group ... The ointment studied is an effective and safe option for the treatment of bacterial skin diseases....

Individualized Homeopathic Medicines in Treatment of Hyperuricemia: Evaluation by Double-Blind, Randomized, Placebo-Controlled Trial.

Hyperuricemia (HU) is a major health issue in India and across the globe. It increases the disease burden and hampers quality of life. This study was aimed at exploring the effects of individualized h... This double-blind, randomized, placebo-controlled trial was conducted on 60 patients suffering from HU in the outpatient department of D. N. De Homoeopathic Medical College and Hospital, Kolkata. Each... The intention-to-treat sample (... IHMs showed significantly better results than placebos in reducing SUA levels and improving quality of life in patients suffering from HU.... CTRI/2019/10/021503; UTN: U1111-1241-1431....

Individualized Homeopathic Medicines in the Treatment of Tinea Corporis: Double-Blind, Randomized, Placebo-Controlled Trial.

Tinea corporis (TC; ringworm or dermatophytosis) is a superficial skin infection caused by... A double-blind, randomized, placebo-controlled, two parallel arms trial was conducted on 62 individuals suffering from TC at the National Institute of Homoeopathy, India. Participants were randomized ... The primary outcome revealed no improvement in either of the groups (... Results were negative on the primary outcome; however, secondary outcomes included some statistically significant results favoring IHMs against placebo after 3 months.... CTRI/2019/11/021999; UTN: U1111-1242-0070....

Effect of Perineural Dextrose Injection on Ulnar Neuropathy at the Elbow: A Randomized, Controlled, Double-Blind Study.

To compare perineural dextrose injection efficacy in the treatment of ulnar neuropathy at the elbow with a control group.... Prospective double-blind randomized control study.... Training and research hospital.... The study was completed with 40 patients with ulnar neuropathy at the elbow.... Normal saline (0.9% sodium chloride) was injected in patients in the control group (n=20; mean age=38.1±10.7 years; median duration of symptoms=4.5 months), and 5% dextrose was injected in patients in... At baseline and weeks 2, 4, and 12, the patients were evaluated with the Visual Analog Scale for pain and the Disabilities of the Arm Shoulder and Hand questionnaire for disability. Electrophysiologic... The improvements in pain, disability, ulnar motor nerve velocity, and ulnar nerve cross-sectional area in the dextrose group were superior to those in the control group, especially at weeks 4 and 12 (... Perineural 5% dextrose may be an effective alternative therapy for those with ulnar neuropathy at the elbow for up to the 12th week....